Normal View Dyslexic View

Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma.

1 March 2022
Randomized clinical trials Upper GI
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz J, Motoyama S et al, for the CheckMate 648 Trial Investigators.
N Engl J Med 2022; 386: 449-462.

A total of 970 patients with advanced oesophageal cancer were studied. The addition of nivolumab with, or without ipilimumab, to standard chemotherapy improved median survival: 13.2 months nivolumab with chemotherapy; 12.7 months with additional ipilimumab; 10.7 months chemotherapy alone. Survival was improved in tumours with PD-L1 expression of one percent or greater.

Comment: Some promise for a difficult disease.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
Info
Copied!